Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
Status:
RECRUITING
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.